Lista de obras - Elena Zamagni - Dominio Público Uruguay

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

artículo científico publicado en 2007

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

scientific article published on 19 August 2019

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

artículo científico publicado en 2013

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

artículo científico publicado en 2013

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2012

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

artículo científico publicado en 2014

Complete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation

artículo científico publicado en 2006

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

artículo científico publicado en 2007

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

artículo científico publicado en 2006

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

artículo científico publicado en 2018

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma

artículo científico publicado en 2020

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials

artículo científico publicado en 2020

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

artículo científico publicado en 2014

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

artículo científico publicado en 2016

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

artículo científico publicado en 2020

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

artículo científico publicado en 2014

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

artículo científico publicado en 2011

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

artículo científico publicado en 2005

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

artículo científico publicado en 2006

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

artículo científico publicado en 2011

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

artículo científico publicado en 2015

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

artículo científico publicado en 2017

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients

artículo científico publicado en 2020

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

artículo científico publicado en 2015

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

artículo científico publicado en 2022

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

artículo científico publicado en 2009

Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma

artículo científico publicado en 2020

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

artículo científico publicado en 2005

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

artículo científico publicado en 2010

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

scientific article published on 10 December 2020

The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.

artículo científico publicado en 2013

Toward a GEP-based PET in myeloma.

artículo científico publicado en 2017

Lista de obras de Elena Zamagni

A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma.

A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial

Bortezomib and dexamethasone as salvage therapy in patients with relapsed/refractory multiple myeloma: analysis of long-term clinical outcomes.

Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

Combination of international scoring system 3, high lactate dehydrogenase, and t(4;14) and/or del(17p) identifies patients with multiple myeloma (MM) treated with front-line autologous stem-cell transplantation at high risk of early MM progression-r

Complete remission upon bortezomib–dexamethasone therapy in three heavily pretreated multiple myeloma patients relapsing after allogeneic stem cell transplantation

Evaluation of bone disease in multiple myeloma patients carrying the t(4;14) chromosomal translocation

First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma

From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives

Functional Imaging for Therapeutic Assessment and Minimal Residual Disease Detection in Multiple Myeloma

Glucose Metabolism Quantified by SUVmax on Baseline FDG-PET/CT Predicts Survival in Newly Diagnosed Multiple Myeloma Patients: Combined Harmonized Analysis of Two Prospective Phase III Trials

HIF-1α inhibition blocks the cross talk between multiple myeloma plasma cells and tumor microenvironment.

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

Long-term results of thalidomide and dexamethasone (thal-dex) as therapy of first relapse in multiple myeloma

Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone

Prognostic relevance of 18-F FDG PET/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation

Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

Second Revision of the International Staging System (R2-ISS) for Overall Survival in Multiple Myeloma: A European Myeloma Network (EMN) Report Within the HARMONY Project

Short-term thalidomide incorporated into double autologous stem-cell transplantation improves outcomes in comparison with double autotransplantation for multiple myeloma

Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma

Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma

Thalidomide-dexamethasone as induction therapy before autologous stem cell transplantation in patients with newly diagnosed multiple myeloma and renal insufficiency

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma

The value of 18F-FDG PET/CT after autologous stem cell transplantation (ASCT) in patients affected by multiple myeloma (MM): experience with 77 patients.

Toward a GEP-based PET in myeloma.